Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors

Published:2015-11-02 Issue:1 Volume:1 Page:
ISSN:2058-7716
Container-title:Cell Death Discovery
language:en
Short-container-title:Cell Death Discovery

Author:

Menachem A,Bodner O,Pastor J,Raz A,Kloog Y

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/cddiscovery201547.pdf

Reference48 articles.

1. Ahuja S, Ernst H . Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987; 10: 303–310.

2. Hunt JL, Tometsko M, LiVolsi VA, Swalsky P, Finkelstein SD, Barnes EL . Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003; 27: 1559–1564.

3. Sipos JA, Mazzaferri EL . The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother 2008; 9: 2627–2637.

4. Shalom-Feuerstein R, Cooks T, Raz A, Kloog Y . Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005; 65: 7292–7300.

5. Elad-Sfadia G, Haklai R, Balan E, Kloog Y . Galectin-3 augments K-ras activation and triggers a ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004; 279: 34922–34930.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of galectins in mediating the adhesion of circulating cells to vascular endothelium;Frontiers in Immunology;2024-05-22

2. Immunomodulation exerted by galectins: a land of opportunity in rare cancers;Frontiers in Immunology;2023-11-08

3. COVID-19 associated thyroid dysfunction and other comorbidities and its management using phytochemical-based therapeutics: a natural way;Bioscience Reports;2023-07

4. Targeting galectin-driven regulatory circuits in cancer and fibrosis;Nature Reviews Drug Discovery;2023-02-09

5. Inhibition of galectins in cancer: Biological challenges for their clinical application;Frontiers in Immunology;2023-01-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3